Intriguingly, RB1 loss was associated with lower recurrence risk in early-stage EGFR-positive NSCLC, contrary to prevailing association with poor outcomes and small cell transformation in the advanced setting, particularly when coaltered with TP53. 27,28 Further studies are needed to elucidate prognostic molecular features specific to early-stage disease. Here, TP53 is linked to non-small cell lung carcinoma.